To Compare the Pulpal Oxygen Saturation Level After Administering Mepivacaine With and Without Vasoconstrictor
NCT ID: NCT04947267
Last Updated: 2021-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2018-05-30
2019-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections
NCT01574807
Comparing Cardiovascular Effects of 1:100,000 and 1:200,000 Epinephrine Solutions
NCT02735018
Assessment of Local Anaesthesia Effectiveness in Symptomatic Irreversible Pulpitis
NCT06862570
: Pulpal Blood Flow With the Use of Intra-nasal Anesthetic
NCT03368391
Effect of Lidocaine/Dexamethasone on the Success of IANB
NCT03531970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
NULL HYPOTHESIS There is no difference between the pulpal oxygen saturation levels after administering 2% mepivacaine with 1:100,000 epinephrine and 3% mepivacaine.
ALTERNATE HYPOTHESIS There is a difference between the pulpal oxygen saturation levels after administering 2% mepivacaine with 1:100,000 epinephrine and 3% mepivacaine.
METHOD Two groups were made with 30 patients in each group. 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) was administered to the patients in Group A whereas 3% mepivacaine (3% Scandonest Plain) was administered to the patients in Group B. Rubber dam application, cavity preparation and composite filling was then done on the selected carious mandibular premolar. Pulpal oxygen saturation levels were recorded after administration of local anesthesia with the Nellcor- PM 10N pulse oximeter and Nellcor D-YS Multisite reusable sensor.
STATISTICAL ANALYSIS The statistical package for social sciences version 21.0 is used for statistical analysis. Mean and standard deviation of the pulpal oxygen saturation levels for filled and unfilled teeth under the effect of 2% mepivacaine with 1:100,000 epinephrine and 3% mepivacaine were recorded. Mixed Way ANOVA will be applied to discern if there is any difference in the pulpal oxygen saturation levels within and between the two groups. Post Hoc Tuckey was applied to identify whether the paired difference is present within groups or between the two groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3% mepivacaine
3% mepivacaine was administered via inferior alveolar nerve block.
3% Mepivacaine Hydrochloride
1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
2% mepivacaine with 1:100,000 epinephrine
2% mepivacaine with 1:100,000 epinephrine was administered via inferior alveolar nerve block.
2% Mepivacaine with 1:100,000 epinephrine
1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3% Mepivacaine Hydrochloride
1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
2% Mepivacaine with 1:100,000 epinephrine
1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Medications: no current medications.
* Both mature vital ipsilateral mandibular premolars:
* Healthy premolar (ICDAS code 0)
* Carious premolar (ICDAS code 4-6).
* Periapical status
* Healthy premolar - Periapical Index. (Code 1).
* Carious premolar - Periapical Index. (Code 1).
* Periodontal status
* Healthy premolar - Classification of periodontal diseases and conditions (Code 0).
* Carious premolar - Classification of periodontal diseases and conditions (Code 0).
Exclusion Criteria
* Pregnant and nursing mothers.
* Class V carious lesions (sensor of pulse oximeter was placed on intact buccal, lingual and cervical surfaces).
* Teeth with extracoronal restorations.
* Teeth with developmental defects and other anomalies.
* Dental trauma.
* Teeth with symptoms of irreversible pulpitis.
15 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Afshan Amjad Ali
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Afshan Amjad Ali
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AFSHAN AMJAD ALI, MSc
Role: PRINCIPAL_INVESTIGATOR
Dow University of Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dow University of Health Sciences
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAli
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.